Portland State University

PDXScholar

Counselor Education Faculty Publications and Presentations

Counselor Education

6-5-2024

Does the Nurse-Led Case Management Benefit Rheumatoid Arthritis Patients in Reducing Distressing Symptoms and C-Reactive Protein: a 2-Year Follow-Up Study in Taiwan

Wei-Chiao Chang Buddhist Tzu Chi Medical Foundation

Hanoch Livneh Portland State University

Hua-Lung Huang Buddhist Tzu Chi Medical Foundation

Hsin-Hua Li Buddhist Tzu Chi Medical Foundation

Ming-Chi Lu Buddhist Tzu chi Medical Foundation Follow this and additional works at: https://pdxscholar.library.pdx.edu/coun_fac

Part of the Medicine and Health Sciences Commons Entering the food of the sciences to this document benefits you.

Citation Details

Chang, W.-C., Livneh, H., Huang, H.-L., Li, H.-H., Lu, M.-C., Lin, M.-C., Chen, W.-J., & Tsai, T.-Y. (2024). Does the nurse-led case management benefit rheumatoid arthritis patients in reducing distressing symptoms and C-reactive protein: a 2-year follow-up study in Taiwan. Frontiers in Medicine, 11.

This Article is brought to you for free and open access. It has been accepted for inclusion in Counselor Education Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: pdxscholar@pdx.edu.

Authors

Wei-Chiao Chang, Hanoch Livneh, Hua-Lung Huang, Hsin-Hua Li, Ming-Chi Lu, Miao-Chiu Lin, Wei-Jen Chen, and Tzung-Yi Tsai

Check for updates

OPEN ACCESS

EDITED BY Alberto Marcos Heredia-Rizo, University of Seville, Spain

REVIEWED BY Carlos Montilla, University Hospital of Salamanca, Spain Mohamed Mortada, Zagazig University, Egypt

*CORRESPONDENCE Wei-Jen Chen ⊠ tough2915@hotmail.com Tzung-Yi Tsai ⊠ dm732024@tzuchi.com.tw

[†]These authors have contributed equally to this work

RECEIVED 20 January 2024 ACCEPTED 06 May 2024 PUBLISHED 06 June 2024

CITATION

Chang W-C, Livneh H, Huang H-L, Li H-H, Lu M-C, Lin M-C, Chen W-J and Tsai T-Y (2024) Does the nurse-led case management benefit rheumatoid arthritis patients in reducing distressing symptoms and C-reactive protein: a 2-year follow-up study in Taiwan. *Front. Med.* 11:1373639. doi: 10.3389/fmed.2024.1373639

COPYRIGHT

© 2024 Chang, Livneh, Huang, Li, Lu, Lin, Chen and Tsai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Does the nurse-led case management benefit rheumatoid arthritis patients in reducing distressing symptoms and C-reactive protein: a 2-year follow-up study in Taiwan

Wei-Chiao Chang^{1†}, Hanoch Livneh^{2†}, Hua-Lung Huang^{3†}, Hsin-Hua Li¹, Ming-Chi Lu^{4,5}, Miao-Chiu Lin⁶, Wei-Jen Chen^{1,7,8,9*} and Tzung-Yi Tsai^{10,11,12*}

¹Department of Chinese Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ²Rehabilitation Counseling Program, Portland State University, Portland, OR, United States, ³Department of Rehabilitation, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ⁴Division of Allergy, Immunology and Rheumatology, Dalin Tzu chi Hospital, Buddhist Tzu chi Medical Foundation, Chiayi, Taiwan, ⁵School of Medicine, Tzu Chi University, Hualien, Taiwan, ⁶Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ⁷Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan, Taiwan, ⁸School of Post-Baccalaureate Chinese Medicine, Tzu Chi Medical Foundation, Chiayi, Taiwan, ⁹Center of Sports Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ¹⁰Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Taiwan, ¹²Department of Nursing, Tzu Chi University of Science and Technology, Hualien, Taiwan, ¹²Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

Background: Rheumatoid arthritis (RA) is a chronic disease and may worsen over time. Today, nurse-led case management (NLCM) has been recommended to improve clinical outcomes for chronic disease patients, yet little is known regarding its impact on pain, fatigue, and C-reactive protein (CRP) among RA patients. We aimed to explore this issue among such groups via a two-group pre- and post-test approach.

Methods: All subjects were recruited from one hospital in Taiwan from January 2017 to June 2018 and assigned to either a 6-month NLCM program in addition to usual care or to a control group that received usual care only. All of them were followed for 2 years. Outcomes of interests were compared at four time points: baseline, the third day after NLCM completion, and at 6 and 24 months after NLCM. Effects between them were tested using the generalized estimating equations (GEE) model after adjusting for differences at baseline.

Results: A total of 50 patients in the NLCM group and 46 in the control group were recruited for data analysis. Results from the GEE model indicated that integrating NLCM into conventional care benefited patients in decreasing levels of pain and fatigue, as well as CRP value. These improvements were still observed for 2 years after NLCM.

Conclusion: NLCM was shown to be helpful in lowering pain, fatigue, and CRP, which implies that NLCM may be a reference in the provision of tailored care for those affected by rheumatism.

KEYWORDS

fatigue, generalized estimating equations, C-reactive protein, nurse-led case management, pain, rheumatoid arthritis

Introduction

Rheumatoid arthritis (RA), an autoimmune disease with systemic inflammation, can cause a wide range of uncomfortable symptoms, from mild joint stiffness to severe functional disability. According to the National Health Interview Survey in 2011–2013, arthritis/ rheumatism was one of the top three leading causes of long-term disability in the United States, causing a tremendous socioeconomic burden (1). A nationwide estimation in the United States showed that annual direct medical costs of newly diagnosed RA were \$20,919 per patient on average, which nearly tripled that of those without RA (\$7,197) (2).

Beyond joint pathology, RA may place people at a higher risk of developing other extra-articular manifestations due to systemic inflammation, such as cardiovascular disease, pulmonary disease, or cancer (3, 4), thereby leading to a higher mortality rate than the general population (5). In such a case, a priori study that followed patients with inflammatory arthritis had found that C-reactive protein (CRP), a commonly used marker of systemic inflammation in RA (6), was an independent predictor of mortality from cardiovascular diseases among this group (7). Thus, in view of the irreversible nature of RA, some specific distressing side effects, such as fatigue and pain, maybe the prevalent symptoms associated with this illness. It has been estimated that one in every two RA patients may experience persistently high levels of fatigue or pain (8, 9). Making matters worse, fatigue not only increased the length of hospitalization by 83% (10) but also caused a conspicuous increase in the likelihood of mortality (11). Therefore, actively implementing a disease management program to minimize the distressing symptoms and inflammation status driven by RA is of paramount importance.

Case management is a widely used care model for patients with chronic diseases who require consistent management over prolonged periods. Specifically, case management represents "a collaborative process of assessment, planning, facilitation, care coordination, evaluation, and advocacy for options and services to meet an individual's and family's comprehensive health needs through communication and available resources to promote quality, cost-effective outcomes" (12, 13). In this model, a specialized nurse often takes on the primary coordination, management, and continuity of care for a specific episode of treatment or intervention (14). Accordingly, the European League Against Rheumatism has put out a call on the integration of case management into routine care to meet quality-of-life needs and to assist with the management of RA symptoms (15). Recently, the use of nurse-led case management (NLCM) for RA patients has attracted a lot of attention, but there is a lack of consensus regarding its impacts. Several studies addressed that the NLCM group experienced remarkable increases in self-efficacy ability and disease activity scores, which were measured by a 28-joint scale (DAS 28) (16-20). Another study also showed that NLCM minimized the RA patients' daily disability assessed by the Health Assessment Questionnaire-Disability Index (21). However, some investigations failed to reveal a significant association between NLCM and DAS 28 scores among RA patients (18, 22–24). The controversy over the effectiveness of NLCM may be related to the neglect of the cluster-specific baseline adjustments and the potential auto-correlations within subjects across time in the priori research, thus prejudicing the findings.

Furthermore, as of now, most of the relevant assessments of NLCM were performed in Western populations (8, 19, 21, 22, 24). The direct application of the results to Chinese populations may be premature because of the intrinsic differences in lifestyle and environmental features between Chinese and Western populations. A noteworthy feature of the priori evidence is that there is a lack of knowledge of the long-term NLCM effects among RA patients, especially in changes of pain, fatigue, and inflammatory symptomatology. To fill the gap, we carried out a study that followed RA participants until a 2-year period following completion of the NCLM program to compare the changes over time in both their subjective symptoms and inflammation status. Such documentation could provide an empirically robust ground for healthcare policymakers to initiate more appropriate care processes for individuals with RA.

Methods

Design and participants

First, this non-randomized follow-up study enrolled RA participants from a rheumatological clinic of the target hospital in Taiwan from January 2017 to June 2018, and all patients were followed for 2 years. To be eligible, the subjects were required to have a diagnosis of RA by rheumatologists, utilizing the classification criteria published by the 2010 American College of Rheumatology and the European League Against Rheumatism (EULAR) (25, 26), and aged 20 years or older at the time of recruitment. Those unable to reliably express their opinions or sign a written consent were excluded. Additionally, we marked all questionnaires with an encryption code instead of any personal identifiers. The required sample size in this study was determined based on previous research, where the effect size was set at 0.33, which concentrated on the fatigue change between the two groups (22), and the power was set to 80% at a significant level at 0.05. Hence, at least 92 participants were required for reliable statistical calculation using PASS 14.0 software (NCSS, Kaysville, UT, USA).

Before participating in the present research, all enrollees received detailed written and verbal information about the aims and protocol of the present study and signed informed consent. Participants were free to withdraw from the study at any time without any penalty. The current study protocol has been approved by the Institutional Review Board and the ethics committee of the target hospital (No. B11004003).



The enrollees were informed that all personal information would be kept confidential.

Procedure

A flowchart of the participant recruitment is displayed in Figure 1. Before the study commenced, all participants were instructed to complete a form that included information on socioeconomic status, prescription medications, and self-health management behaviors. In addition, the information on the outcome indicators was assessed at four time points: baseline (T0), 3 days after completion of NLCM (T1), 6 months after NLCM completion (T2), and 24 months after completion of NLCM (T3). One independent interviewer, who was blinded to the study group assignment, took responsibility for obtaining informed consent and administering all measures during

the study timeframe. To minimize the dropout rate, all enrollees were telephoned and reminded to return to the hospital for the completion of assessments as scheduled.

Intervention

Patients with RA seeking care in the target hospital were referred to the following process. First, they were informed of their right to opt to receive either conventional care or conventional care plus NLCM. Those joining the conventional care would receive health education lasting for 15 min per medical visit from ward nurses as scheduled, consisting of consultation in terms of disease symptoms, related treatments, and the doctor's orders. In this study, they would be deemed the non-NLCM group.

By contrast, those enrolling in the NLCM group would receive the consecutive intervention programs that were developed by an extensive review of the literature and discussions with experts. The NLCM consisted of three key components: (1) a series of RA-related education sessions, including disease etiology, complications, and selfcare management; (2) instructions on the individual exercise program, containing explanations and demonstrations of the various steps; and (3) monthly telephone follow-up evaluation to identify difficulties faced by the participants, monitor their daily practice, and answer any questions. The first two components were delivered through one-to-one health education sessions lasting for approximately 50 min each, once a month for 6 consecutive months. An educational booklet on the relevant issues discussed was also given to each participant as a guide. Additionally, they were instructed to report time spent on and frequency of exercise per week using the electronic diary provided at a freeware instant-communications app LINE. As a whole, we used an interactive learning environment to allow enrollees to discuss the impact of illness, the treatment received, and changes in self-image and relationships with friends and family. All involved strategies were systematically planned and modified on the basis of the individualized therapeutic regimen offered to the patient. The nursing case manager offered consultation with patient's family and other healthcare providers of the medical team as needed.

Collectively, the NLCM in the target hospital integrated a multicomponent intervention comprised of health education and professional advice, referring patients to other healthcare team members, discussing a daily life plan, making medical appointments, and conducting telephone follow-up provided by the trained registered nurse. This NLCM program was conducted in one rheumatology health education room and delivered by one specific nurse case manager who had more than 10 years of experience in nursing care for RA patients and possessed the NLCM certification.

Outcome indicators

In this study, we collected three primary outcome indicators, including fatigue, pain, and CRP. These outcome indicators were measured before and after the initiation of intervention, all of which were obtained from patient's medical records.

In the target hospital, levels of fatigue and pain were both determined via the self-reported Visual Analog Scale (VAS), which has been extensively used and validated across the rheumatic disease spectrum (27, 28). VAS is used to assess the intensity and frequency of subjective pain experienced by the patient on an 11-point numerical scale, ranging from 0 to 10, where higher scores reflect a more severe degree of fatigue or pain experienced (28, 29). The reliability and validity of VAS measures have been previously confirmed (30). The VAS was demonstrated to possess acceptable psychometric properties, with a concurrent validity of 0.90 and an intraclass correlation coefficient of 0.94 (31). In this study, the Cronbach's alpha scores for pain and fatigue were 0.85 and 0.89, respectively. Apart from these two subjective symptoms, we used CRP as the major marker of inflammation status. CRP is a protein produced by the liver and is a commonly used marker of systemic inflammation for autoimmune diseases (6).

Covariates

The demographic variables herein included age, sex, marital status, educational level, job status, household status, and lifestyle factors (smoking and exercise habits). Patients who answered "currently" or "yes/past" to the question on smoking were classified as smokers. Patients who exercised 3 or more days per week were classified as having regular exercise. Disease characteristics included comorbidities (diabetes mellitus, hypertension, heart disease, or stroke), body mass index, DAS 28, duration of RA, and use of conventional disease-modifying anti-rheumatic drugs (DMARDs) and biological agents. The latter indicator comprised adalimumab, etanercept, infliximab, rituximab, and tocilizumab. The last two indicators were defined as using the relevant drugs for more than 3 months following disease onset.

Evaluation of data

The descriptive statistics, including the mean, standard deviation (SD), and percentage, were used to describe the distributions. We then compared the distributions of demographic and disease characteristics between the two groups using the t-test and χ^2 test as applicable. Additionally, intergroup differences before and after the intervention for each of the outcomes were tested using the generalized estimating equations (GEE) model, a statistical procedure that extends the capabilities of generalized linear models (GLM) for analyzing longitudinal data or other clustered response data (32). Each GEE model produces estimates of the time effect (baseline as the reference category), intervention effect (control group as the reference category), and effect of the interaction term between intervention and time after covariate adjustment (33). The effect of the intervention, as it varies over time, can, then, be confirmed, provided that the interaction term was pronounced. Covariates, where the difference reached statistical significance at baseline, were identified as the control variables in the GEE model. Robust standard errors were selected to calculate the significance of parameter estimates, and the autoregressive first-order working correlation matrix was utilized to adjust for the time effect (33). All analyses were conducted using SPSS 22.0 (Chicago, IL, USA), and all statistical tests were performed at the two-tailed significance level of 0.05.

TABLE 1 Demographic and clinical data by two groups.

Variable	All participants (<i>N</i> = 96)		NLCM group (<i>n</i> = 50)		Non-NLCM group (<i>n</i> = 46)		p
	N	%	N	%	N	%	
Sex (female)	79	82.3	38	76.0	41	89.1	0.09
Marital status (married)	81	84.4	44	88.0	37	80.4	0.31
Educational level (\geq 9th grade)	54	56.2	27	54.0	27	58.7	0.64
Household status (Cohabitating)	89	92.7	46	92.0	43	93.5	0.78
Monthly income (\leq 30,000 NTD)	52	54.2	27	54.0	25	54.3	0.97
Regular exercise	34	35.4	24	48.0	18	39.1	0.15
Cigarette smoking	14	14.6	9	18.0	5	10.9	0.32
Conventional DMARDs	79	82.3	42	84.0	37	80.4	0.65
Biological agents use	34	35.0	18	36.0	16	34.8	0.90
Comorbidities	68	71.0	34	68.0	34	73.9	0.52
	Mean	SD	Mean	SD	Mean	SD	
Age (years)	53.80	10.5	56.66	10.4	50.74	10.8	0.01
Disease duration [†]	5.1	4.3	3.7	3.5	6.6	4.5	0.01
Body mass index (Kg/m ²)	23.7	3.8	23.2	3.4	24.2	4.1	0.21
DAS 28 [†]	4.5	1.6	5.0	1.4	3.9	1.5	< 0.01
C-reactive protein	1.5	1.2	1.9	1.1	1.0	1.3	0.06
Pain [†]	5.7	2.4	6.9	2.8	4.4	2.5	< 0.01
Fatigue [†]	5.2	3.3	6.3	2.9	4.0	3.3	< 0.01

[†]Data were expressed as mean ± standard deviation.

NLCM, nurse-led case management; DAS 28, disease activity score measured by a 28 joint-scale; NTD, New Taiwan Dollar.

Results

Baseline characteristics

Demographic and clinical characteristics of the study sample are given in Table 1. During the study period, a total of 96 RA patients were recruited, consisting of 50 in the NLCM group and 46 in the non-NLCM group. None of the participants dropped out or were lost to follow-up. The mean (SD) age was 56.6 (10.3) years in the NLCM group and 50.7 (10.8) years in the control group, respectively. Most participants were women and had comorbidities at the time of the study, and 35% of them had been treated with at least one biological agent. Demographic and clinical characteristics between them were comparable at the baseline, except for age and the duration of RA. Compared with the non-NLCM group, subjects in the NLCM group were found to experience higher scores of DAS 28, pain, and fatigue at baseline (all $p \leq 0.01$).

Comparison of effect of NLCM versus conventional care

After taking into consideration the significant variables at baseline (displayed in Table 1), the multivariate analysis using the GEE procedure indicated that a baseline difference occurred regarding fatigue score between the NLCM and the non-NLCM groups (p = 0.03) (Table 2). Fatigue scores at T1, T2, and T3 were similar to those measured at T0, implying that a maturation effect

might not have arisen. Following consideration of baseline differences in fatigue, age, DAS 28, and disease duration by GEE procedure, the reduction slope of fatigue scores was still larger in the NLCM group than in the non-NLCM group, irrespective of elapsed time (Figure 2).

As to pain, the GEE model indicated a difference at T1 and T3, which implied that a maturation effect might occur regardless of the use of intervention employed. After adjustment for age, DAS 28, disease duration, inherent pain level, and maturation effects, we found that NLCM was helpful in reducing pain for RA patients during the study timeframe as compared with the control group, yielding statistical differences of $\beta = -1.29$ (T1), $\beta = -1.49$ (T2), and $\beta = -1.99$ (T3) (Table 2). The change in pain levels between the two groups is displayed in Figure 3.

Regarding CRP, maturation effects were detected at T2 and T3 since CRP levels measured at both T2 and T3 were greater than those measured at T0 (both p < 0.05, Table 2). Additionally, the baseline inflammatory status was similar for the two groups (p = 0.25, Table 2). After adjusting for the initial differences in age, DAS 28, disease duration, and maturation effects, the mean value of CRP in the NLCM group was found to be lower than in the non-NLCM group at both T1 ($\beta = -0.66$; p = 0.04), T2 ($\beta = -0.94$; p = 0.01), and T3 ($\beta = -0.72$; p = 0.03) (Table 2). These benefits were still detected for 2 years after the NLCM program (Figure 4).

Furthermore, to minimize the baseline imbalances in this comparative study, we carried out one sensitivity analysis where each selected NLCM case was randomly matched to one control without NLCM use via the propensity score matching (34). The

Variables	Fatigue		CI	RP	Pain							
	β	р	β	р	β	р						
Intercept	3.33	<0.01	0.67	0.01	2.56	0.41						
NLCM vs. non-NLCM	2.43	0.03	-0.05	0.25	1.54	0.01						
Time												
T1 vs. T0	-0.36	0.46	0.98	0.06	-0.66	0.01						
T2 vs. T0	-0.59	0.10	1.08	<0.01	-1.05	0.16						
T3 vs. T0	-0.22	0.71	0.45	0.02	-1.40	<0.01						
Interaction term												
Interaction of T1×NLCM	-1.32	0.04	-0.66	0.04	-1.29	0.03						
Interaction of T2×NLCM	-1.42	0.02	-0.94	0.01	-1.49	0.02						
Interaction of T3×NLCM	-1.76	<0.01	-0.72	0.03	-1.99	0.01						
DAS 28	0.65	<0.01	0.63	0.01	0.90	0.01						
Disease duration (year)	-0.04	0.12	-0.03	0.25	-0.02	0.54						
Age (year)	-0.02	0.23	0.02	<0.01	0.01	0.56						

TABLE 2 Regression coefficients associated with nurse-led case management (NLCM) on patients with rheumatoid arthritis were obtained by generalized estimating equation model (*n* = 96).

T0, prior to NLCM inception; T1, the 3th day after NLCM commencement; T2, 6 months after NLCM completion; T3, 2 years after the completion of NCLM. Interaction of T1 × NLCM, difference between NLCM and control group in change from T0 to T1. Interaction of T2 × NLCM, difference between NLCM and control group in change from T0 to T3. CRP, C-reactive protein; DAS 28, disease activity score measured by a 28-joint scale.



propensity score was calculated using logistic regression derived from patients' demographics and baseline comorbidities at enrollment. Thereafter, a total of 26 NLCM users and 26 control users were included after propensity score matching and no conspicuous differences were found between the two groups, indicating the matched intervention and comparison groups were comparable in terms of baseline characteristics. The reanalysis based on the GEE procedure indicated that NLCM was still significantly related to reductions in levels of pain (T1=-2.54, p < 0.01; T2=-2.20, p = 0.03; T3=-1.92, p = 0.04), fatigue (T1=-1.27, p = 0.02; T2=-1.31, p = 0.01; T3=-1.25, p < 0.01), and CRP (T1=-0.36, p = 0.03; T2=-0.51, p = 0.01; T3=-0.31, p = 0.02), among the enrollees.

Discussion

While the effects of NLCM have been recognized, few studies have directly examined this association in persons with RA, especially the long-term effects of NLCM on the reduction of fatigue, pain, and intrinsic inflammation. The GEE model used in this study provided further control of participants' attributes at baseline and temporal maturation effect, enabling us to evaluate the effects of NLCM more precisely. As compared to the participants in the non-NLCM group, we discovered that levels of fatigue, pain, and CRP decreased more in the NLCM group, which implied that the implementation of the 6-month NLCM program into routine care may indeed bring benefits for RA patients. The





beneficial impacts herein were consistent with earlier reports (17, 18, 24, 35).

Notably, the findings of our study further supported that the beneficial effects could be maintained for 2 years after the completion of NLCM. We inferred that the implementation by a nursing case manager in the form of one-on-one consultation/education and regular follow-up were the keys. It has been suggested that continuing education activities contributed to better clinical manifestation in chronic disease patients (13). Unlike the traditional care approach from one direction, a highly interactive approach and colored images utilized in the NLCM might be more beneficial in engaging patients in the health information they are learning and assisting them in making appropriate plans for disease management, thereby increasing their at-home self-care skills to diminish the disturbances caused by the RA symptoms. In addition, regular follow-ups may ensure the long-term compliance of the patients. Including fitting physical activity, a key component of NLCM used in this study, may account for the beneficial effect reported herein. A growing body of research findings has indicated that reasonable intermediate exercise loads may decrease leptin levels in serum, which is a well-known adipocytokine that can elevate mRNA and protein expression of inflammatory precursor substances, such as tumor necrosis factor- α (TNF- α) (36). An animal study reported a positive correlation between levels of leptin and interleukin-6 (IL-6) (37). Moreover, the secretions of IL-6 and TNF- α played a role in the development of fatigue in both autoimmune and non-autoimmune diseases via neuroinflammation and neuroprogressive changes (38, 39). Altogether, we propose that early inclusion of a fitting exercise program to the routine pharmacological therapy, as well as prolonging its use, may serve to psychologically benefit RA patients.

The findings of the present study revealed a difference in CRP levels between the NLCM and non-NLCM groups. Since no relevant studies were found to examine the long-term impact of NLCM on CRP in these patients, a direct comparison with earlier studies is impossible. We speculated that direct participation in NLCM programs insensibly contributes to increased socialization and individual self-efficacy, which in turn may assist patients in mitigating the physical and emotional burden of the illness. The concept of selfefficacy has been proven to significantly influence behavior changes that buffer the potential negative effects of various diseases. For example, a recent cross-sectional study by Hladek and colleagues found an association between coping-associated self-efficacy and low serum IL-6 and TNF- α in senior adults (40). These physiologic mediators are known to play indispensable roles in synthesizing and secreting CRP (41). Despite this preliminary evidence, the underlying mechanism of how NLCM alleviates CRP is not well understood, which implies that future large-scale studies to verify the effect of NLCM against inflammatory responses reported herein should be undertaken.

GEE, an extension of the GLM procedure, could model a known function of the marginal expectation of the dependent variable as a linear function of explanatory variables. On top of that, this study was the first to investigate the relation between NLCM and changes in pain, fatigue, and systemic inflammation in RA patients through a long-term follow-up perspective, enabling authors to cautiously shed light on NLCM impacts. Notwithstanding the foregoing issues, this study may be affected by some limitations. First, the sampled participants were selected from a single hospital in Taiwan and accordingly, the generalization of study results may be limited. Second, the subjective scale was used to measure pain or fatigue, so further studies employing more objective measures of psychological change are warranted. Third, the experimental group in this study comprised patients who agreed to take part in the program. Thus, willingness to participate might bias the results of this study. To address this issue, we set objective criteria to balance the baseline differences between the two groups through the evaluation of demographic and disease characteristics, as shown in Table 1. Furthermore, we capitalized on the GEE model to control for possible baseline differences between the two groups (if any) and further consider potential maturation effects. Additionally, the initial descriptive analysis suggested that NLCM users indeed exhibited poorer manifestations than did non-NLCM users, yet they displayed substantial reductions in pain, fatigue, and CRP than did the non-users, implying that the present findings are likely to underestimate, rather than overestimate, the effects of NLCM. Taken together, we concluded that baseline differences between the two groups, in all likelihood, did not distort the present findings. Fourth, even though we used the GEE model to control for baseline differences between the two groups, the application of an observational design herein may still be affected by potential confounders that were not included in the models (33). We conducted a sensitivity analysis by utilizing the propensity score with one-to-one matching to reduce the imbalance of the characteristics between the two groups (34). The reanalysis based on the GEE procedure indicated that NLCM was still related to reductions in levels of pain, fatigue, and CRP, suggesting that the baseline imbalance did not appreciably impact the relationship reported herein. To lend further credence to the present findings, future prospective randomized trials are needed to overcome the experimental weaknesses of this study via employing psychometrically sound measurements, which would allow for more efficient approaches to disease management of RA.

Conclusion

On the whole, this study supported the idea that adding the NLCM to conventional care can ameliorate the distressing symptoms and systemic inflammation of RA patients. Findings demonstrated that participants in the NLCM group experienced lower levels of pain, fatigue, and CRP after the intervention than their control counterparts. Notably, we observed that these beneficial effects were maintained for 2 years after the completion of NCLM. The findings

of this study may be a reference in facilitating the implementation of the NLCM program among patients with newly diagnosed RA for long-term survival benefits. Due to the potential drawbacks regarding recruitment strategy and data collection, the effects of NLCM still must be further elucidated via well-designed, long-term randomized controlled trials.

Data availability statement

Data are available upon reasonable request. The data used and/or analyzed during the current study are available from the corresponding authors only on academic research request.

Ethics statement

The studies involving humans were approved by Institutional Review Board and the Ethics Committee of Buddhist Dalin Tzu Chi Hospital No. B11004003. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

W-CC: Formal analysis, Investigation, Validation, Writing – review & editing, Writing – original draft. HL: Methodology, Writing – review & editing. H-LH: Data curation, Investigation, Writing – original draft. H-HL: Conceptualization, Investigation, Validation, Writing – original draft. M-CLu: Data curation, Project administration, Writing – original draft. M-CLi: Conceptualization, Investigation, Writing – original draft. W-JC: Formal analysis, Funding acquisition, Project administration, Validation, Writing – original draft. T-YT: Conceptualization, Formal analysis, Methodology, Project administration, Validation, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants, including DTCRD111-I-24 and TCMF-CM2-111-07. The funding source had no role in this work.

Acknowledgments

The authors thank the co-investigators in this project and the patients who responded to our survey.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Centers for Disease Control and Prevention. National Center for Health Statistics. (2019) Available at:https://www.cdc.gov/arthritis/data_statistics/disabilities-limitations. htm

2. Chen CI, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US medicare population: co-morbidities, health-care resource utilization and costs. *Rheumatol Adv Pract.* (2018) 2:rky005. doi: 10.1093/rap/rky005

3. Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. *Mediat Inflamm.* (2014) 2014:545493:1–24. doi: 10.1155/2014/545493

4. Cook MJ, Bellou E, Bowes J, Sergeant JC, O'Neill TW, Barton A, et al. The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK biobank. *Rheumatology*. (2018) 57:2172–82. doi: 10.1093/rheumatology/ key224

5. Houge IS, Hoff M, Thomas R, Videm V. Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population – the Nord-Trøndelag health study. *Sci Rep.* (2020) 10:3593. doi: 10.1038/s41598-020-60621-2

6. D'Cruz LG, McEleney KG, Cochrane C, KBC T, Shukla P, Gardiner PV, et al. Assessment of a dried blood spot C-reactive protein method to identify disease flares in rheumatoid arthritis patients. *Sci Rep.* (2020) 10:21089. doi: 10.1038/s41598-020-77826-0

7. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. *Arthritis Rheum*. (2005) 52:2293–9. doi: 10.1002/ art.21204

8. Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid arthritis: the impact of mental health on disease: a narrative review. *Rheumatol Ther*. (2020) 7:457–71. doi: 10.1007/s40744-020-00217-4

9. Druce KL, Jones GT, Macfarlane GJ, Verstappen SM, Basu N. The longitudinal course of fatigue in rheumatoid arthritis: results from the Norfolk arthritis register. *J Rheumatol.* (2015) 42:2059–65. doi: 10.3899/jrheum.141498

10. Strand V, Shah R, Atzinger C, Zhou J, Clewell J, Ganguli A, et al. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. *Curr Med Res Opin*. (2020) 36:161–8. doi: 10.1080/03007995.2019.1658974

11. Basu N, Yang X, Luben RN, Whibley D, Macfarlane GJ, Wareham NJ, et al. Fatigue is associated with excess mortality in the general population: results from the EPIC-Norfolk study. *BMC Med.* (2016) 14:122. doi: 10.1186/s12916-016-0662-y

12. Case Management Society of America. What is a case manager? (2021) Available at:https://cmsa.org/who-we-are/what-is-a-case-manager/.

13. Martínez-González NA, Berchtold P, Ullman K, Busato A, Egger M. Integrated care programmes for adults with chronic conditions: a meta-review. *Int J Qual Health Care*. (2014) 26:561–70. doi: 10.1093/intqhc/mzu071

14. Primdahl J, Wagner L, Hørslev-Petersen K. Self-efficacy as an outcome measure and its association with physical disease-related variables in persons with rheumatoid arthritis: a literature review. *Musculoskeletal Care.* (2011) 9:125–40. doi: 10.1002/msc.210

15. van Eijk-Hustings Y, van Tubergen A, Boström C, Braychenko E, Buss B, Felix J, et al. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. *Ann Rheum Dis.* (2012) 71:13–9. doi: 10.1136/annrheumdis-2011-200185

16. Ndosi M, Lewis M, Hale C, Quinn H, Ryan S, Emery P, et al. The outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial. *Ann Rheum Dis.* (2014) 73:1975–82. doi: 10.1136/annrheumdis-2013-203403

17. Lu MC, Guo HR, Livneh H, Lin MC, Lai NS, Tsai TY. The effectiveness of nurseled case management for patients with rheumatoid arthritis in Taiwan. *Int J Clin Pract.* (2020) 74:e13443. doi: 10.1111/ijcp.13443

18. de Thurah A, Esbensen BA, Roelsgaard IK, Frandsen TF, Primdahl J. Efficacy of embedded nurse-led versus conventional physician-led follow-up in rheumatoid arthritis: a systematic review and meta-analysis. *RMD Open*. (2017) 3:e000481. doi: 10.1136/rmdopen-2017-000481

19. Ndosi M, Vinall K, Hale C, Bird H, Hill J. The effectiveness of nurse-led care in people with rheumatoid arthritis: a systematic review. *Int J Nurs Stud.* (2011) 48:642–54. doi: 10.1016/j.ijnurstu.2011.02.007

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

20. Wang J, Zou X, Cong L, Liu H. Clinical effectiveness and cost-effectiveness of nurse-led care in Chinese patients with rheumatoid arthritis: a randomized trial comparing with rheumatologist-led care. *Int J Nurs Pract.* (2018) 24:1. doi: 10.1111/ jjn.12605

21. Tokem Y, Argon G, Keser G. Case management in care of Turkish rheumatoid arthritis patients. *Rehabil Nurs*. (2011) 36:205–13. doi: 10.1002/j.2048-7940.2011. tb00197.x

22. Koksvik HS, Hagen KB, Rødevand E, Mowinckel P, Kvien TK, Zangi HA. Patient satisfaction with nursing consultations in a rheumatology outpatient clinic: a 21-month randomised controlled trial in patients with inflammatory arthritides. *Ann Rheum Dis.* (2013) 72:836–43. doi: 10.1136/annrheumdis-2012-202296

23. Larsson I, Fridlund B, Arvidsson B, Teleman A, Bergman S. Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy. *J Adv Nurs*. (2014) 70:164–75. doi: 10.1111/jan.12183

24. Sousa F, Santos E, Cunha M, Ferreira R, Marques A. Effectiveness of nursing consultations in people with rheumatoid arthritis: systematic review. *Revista de Enfermagem Referência*. (2017) IV Série:147–56. doi: 10.12707/RIV17013

25. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheum*. (2010) 62:2569–81. doi: 10.1002/art.27584

26. Kasturi S, Goldstein BL, Malspeis S, Karlson EW, Costenbader KH. Comparison of the 1987 American College of Rheumatology and the 2010 American College of Rheumatology/European league against rheumatism criteria for classification of rheumatoid arthritis in the Nurses' health study cohorts. *Rheumatol Int.* (2014) 34:407–11. doi: 10.1007/s00296-013-2865-2

27. Santos EJF, Duarte C, da Silva JAP, Ferreira RJO. The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. *Rheumatology*. (2019) 58:v3-9. doi: 10.1093/rheumatology/kez351

28. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short Form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). *Arthritis Care Res.* (2011) 63:S240–52. doi: 10.1002/acr.20543

29. Pope JE. Management of fatigue in rheumatoid arthritis. *RMD Open*. (2020) 6:e001084. doi: 10.1136/rmdopen-2019-001084

30. Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German society of allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT section, in collaboration with the working group on clinical immunology, Allergology and environmental medicine of the German Society of Otorhinolaryngology, head and neck surgery (DGHNOKHC). *Allergo J Int.* (2017) 26:16–24. doi: 10.1007/s40629-016-0006-7

31. Hasson D, Arnetz BB. Validation and findings comparing VAS vs. Likert scales for psychosocial measurements. *Int Electron J Health Educ.* (2005) 8:178–92.

32. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*. (1986) 42:121-30. doi: 10.2307/2531248

33. Overall JE, Tonidandel S. Robustness of generalized estimating equation (GEE) tests of significance against misspecification of the error structure model. *Biom J.* (2004) 46:203–13. doi: 10.1002/bimj.200210017

34. Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. *BMC Med Res Methodol*. (2012) 12:70. doi: 10.1186/1471-2288-12-70

35. Garner S, Lopatina E, Rankin JA, Marshall DA. Nurse-led care for patients with rheumatoid arthritis: a systematic review of the effect on quality of care. *J Rheumatol.* (2017) 44:757–65. doi: 10.3899/jrheum.160535

36. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. *Nat Rev Immunol.* (2011) 11:607–15. doi: 10.1038/nri3041

37. Tazawa R, Uchida K, Fujimaki H, Miyagi M, Inoue G, Sekiguchi H, et al. Elevated leptin levels induce inflammation through IL-6 in skeletal muscle of aged female rats. *BMC Musculoskelet Disord.* (2019) 20:199. doi: 10.1186/s12891-019-2581-5

38. Grygiel-Górniak B, Puszczewicz M. Fatigue and interleukin-6 - a multi-faceted relationship. *Reumatologia.* (2015) 53:207–12. doi: 10.5114/reum.2015.53998

39. Bossola M, Di Stasio E, Giungi S, Rosa F, Tazza L. Fatigue is associated with serum interleukin-6 levels and symptoms of depression in patients on chronic hemodialysis. *J Pain Symptom Manag.* (2015) 49:578–85. doi: 10.1016/j.jpainsymman.2014.07.009

40. Hladek M, Gill J, Lai C, Lorig K, Szanton S. High coping self-efficacy associated with lower sweat inflammatory cytokines in adults: a pilot study. *Biol Res Nurs.* (2020) 22:75–81. doi: 10.1177/1099800419870607

41. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol.* (2018) 9:754. doi: 10.3389/fimmu.2018.00754